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Electrohydraulic High-Energy
Shock-Wave Treatment for
Chronic Plantar Fasciitis
BY JOHN A. OGDEN, MD, RICHARD G. ALVAREZ, MD,
RICHARD L. LEVITT, MD, JEFFREY E. JOHNSON, MD, AND MARIE E. MARLOW, RN
Investigation performed at the Atlanta Medical Center and the Skeletal Educational Association, Atlanta, Georgia; Southern Orthopaedic
Foot and Ankle Center, Chattanooga, Tennessee; HealthSouth Doctor’s Hospital, Coral Gables, Florida; University of Rochester School of
Medicine, Rochester, New York; Washington University School of Medicine, St. Louis, Missouri; Baylor University School of Medicine,
Houston, Texas; American Sports Medicine Institute, Birmingham, Alabama; and University of Texas Medical Branch, Galveston, Texas

Background: Plantar fasciitis is a common foot disorder that may be resistant to nonoperative treatment. This study
evaluated the use of electrohydraulic high-energy shock waves in patients who failed to respond to a minimum of six
months of antecedent nonoperative treatment.
Methods: A randomized, placebo-controlled, multiply blinded, crossover study was conducted. Phase 1 consisted of
twenty patients who were nonrandomized to treatment with extracorporeal shock waves to assess the phase-2 study
protocol. In phase 2, 293 patients were randomized and an additional seventy-one patients were nonrandomized. Following ankle-block anesthesia, each patient received 100 graded shocks starting at 0.12 to 0.22 mJ/mm2, followed
by 1400 shocks at 0.22 mJ/mm2 with use of a high-energy electrohydraulic shock-wave device. Patients in the placebo group received minimal subcutaneous anesthetic injections and nontransmitted shock waves by the same protocol. Three months later, patients were given the opportunity to continue without further treatment or have an
additional treatment. This allowed a patient in the active treatment arm to receive a second treatment and a patient
who received the placebo to cross over to the active treatment arm. Patients were followed at least one year after the
final treatment.
Results: Treatment was successful in seventeen of the twenty phase-1 patients at three months. This improved to
nineteen (95%) of twenty patients at one year and was maintained at five years. In phase 2, three months after treatment, sixty-seven (47%) of the 144 actively treated patients had a completely successful result compared with fortytwo (30%) of the 141 placebo-treated patients (p = 0.008). At one year, sixty-five of the sixty-seven actively treated,
randomized patients maintained a successful result. Thirty-six (71%) of the remaining fifty-one nonrandomized patients had a successful result at three months. For all 289 patients who had one or more actual treatments, 222
(76.8%) had a good or excellent result. No patient was made worse by the procedure.
Conclusions: The application of electrohydraulic high-energy shock waves to the heel is a safe and effective noninvasive method to treat chronic plantar fasciitis, lasting up to and beyond one year.
Level of Evidence: Therapeutic study, Level I-1a (randomized controlled trial [significant difference]). See Instructions to Authors for a complete description of levels of evidence.

E

xtracorporeal shock waves have been applied since
1990, principally in Europe, for the treatment of numerous musculoskeletal disorders1-4. One of the initial
treatment concepts was the noninvasive dissolution of a calcific mass in the rotator cuff, similar to the break-up of a kidney stone (lithotripsy)5-7. Several musculoskeletal entities that
have been treated include calcific tendinitis of the shoulder,
lateral epicondylitis, delayed union and nonunion of fractures,
chronic plantar fasciitis, Achilles and patellar tendinopathies,

and osteonecrosis of the femoral head1-9. Basic-science studies
increasingly are providing an understanding of the physiologic mechanisms of pain relief (often immediate) and the
modification and repair of the target tissue, which usually requires weeks to months to occur10-29.
Extracorporeal shock-wave treatments have been applied to patients with chronic plantar fasciitis who have failed
to respond to multiple conservative pharmacologic and therapeutic interventions29-38. Recent randomized, controlled stud-
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ies have been published but with varying results because of
differences in study design, direction of the shock-wave delivery,
energy levels, size (volume) of the focused energy ellipsoid (f2)
that is transcutaneously transmitted to the fascia, and method
of forming the shock wave (electrohydraulic, electromagnetic,
and piezoelectric)32, 39-52. One study found that satisfactory results were maintained five years following electromagnetic
shock-wave treatment43.
Randomized, placebo-controlled clinical trials for musculoskeletal applications of high-energy shock waves have been
conducted in the United States43,46. One trial led to Food and
Drug Administration approval of the use of electrohydraulic
high-energy extracorporeal shock waves for the treatment of
plantar fasciitis in October 200044,53.
The present study assessed both the short and long-term
results of the application of high-energy electrohydraulic
shock waves in the treatment of plantar fasciitis. We hypothesized that the likelihood of a successful result would be better
in patients receiving active treatment than in patients receiving a placebo. We further hypothesized that nonrandomized
patients would have an outcome equal to or greater than that
for the treated randomized patients.
Methods
his study was conducted between 1996 and 2003. Phase-1
and phase-2 protocols were approved sequentially by the
Food and Drug Administration. Study approvals were for a
specific shock-wave generation device, the OssaTron (HealthTronics Surgical Services, Marietta, Georgia, and High Medical Technologies, Lengwil, Switzerland). This device generates
repetitive, high-energy shock waves by the electrohydraulic
method and transmits them transcutaneously through the
plantar skin into the target tissue. At all participating institutions, the study was conducted by members of the Department of Orthopaedics and was approved by the institutional
review board.
Phase 1 involved the nonrandomized application of extracorporeal shock waves to patients with chronic plantar fasciitis to assess any procedural or safety risks, to judge the
potential efficacy, and to assess the planned phase-2 study
protocol. All phase-1 study patients received active shockwave treatments. The phase-1 patients were allowed to receive
a second treatment at three months if they were dissatisfied
with the initial results, on the basis of the four outcome criteria proposed for phase 2.
Phase 2 involved a prospective, randomized, placebocontrolled, physician and patient-blinded, multicenter evaluation to determine both the safety and the effectiveness of this
treatment method. Patients who received an actual treatment
were given the opportunity to have a second treatment if they
failed one or more of the four specific primary outcome parameters. Patients who received a placebo treatment similarly
could choose to receive one or two actual treatments (cross over).
All retreatment and crossover treatment decisions were made,
according to protocol, three months after the initial treatment.
Patients were not informed as to which study arm they were in
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initially. An additional group of nonrandomized patients was
treated to allow training of the physician investigators. These
patients also were given the option of a second treatment at
three months if they failed any of the outcome parameters. All
of these nonrandomized patients in the training arm, who
were comparable with phase-1 patients, were aware that they
had an actual treatment.
A minimum of two physician investigators participated
at each study site. One investigator served as the treatmentblinded evaluator, both for the baseline patient assessment
(according to specific inclusion and exclusion criteria detailed
in the Appendix) as well as for the follow-up evaluations. This
physician was not allowed to observe patient treatment. The
actual procedure was performed by a second trained physician
who was aware of the specific treatment rendered (with use of
a sealed randomization envelope), but who did not play any
role in evaluating the patient before or after treatment.
Subjects were randomized with use of blocks stratified
by study site. Randomization was done by a statistician (StatTech Services) using numbered envelopes that were prepared
at a central facility and subsequently distributed to each treatment facility. When a patient was to be treated, the study
coordinator was contacted and randomly assigned a specific
numbered envelope for the patient.
In both phases of the overall study, chronic heel-pain
syndrome was defined as moderate-to-severe heel pain in the
involved foot at the origin (enthesis) of the proximal plantar
fascia at the medial calcaneal tuberosity that had persisted for
at least six months.
There were three important criteria for inclusion in the
study. (1) The patient had to have failed to respond after at
least three attempts of interventional conservative treatment,
which could include at least two prior courses of physical therapy (Achilles tendon and plantar fascia-stretching exercises)
and the use of orthotic devices (heel cup, molded shoe insert,
night splint, or cast) and at least one prior course of pharmacologic treatment (aspirin, acetaminophen, nonsteroidal antiinflammatory drug, or corticosteroid injection). If the patient
had a corticosteroid injection, extracorporeal shock waves
were not administered unless at least four weeks had elapsed
since the injection. (2) The objective assessment of pain in the
proximal plantar fascia by an investigator, using a pain measurement pressure device (dolorimeter), was ≥5 cm on a 10cm visual analog scale54,55. (3) The patient self-assessment of
pain after the first five minutes of walking in the morning was
≥5 cm on the 10-cm visual analog scale.
All patients underwent monofilament sensory testing
(10-g retractable monofilament; Smith and Nephew, Germantown, Wisconsin) according to Semmes-Weinstein criteria to
screen for possible peripheral neuropathy56-58. Any patient who
tested positive at two or more of ten sites was excluded from
the study. Monofilament testing also was done at each posttreatment evaluation.
Patients with bilateral involvement were allowed to have
treatment of only one foot. However, these patients were discouraged from participating during the enrollment evaluation
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because of the possible pharmacologic treatment of the contralateral heel at or near the critical three-month evaluation
point that might adversely affect one of the four primary outcome criteria. Any patient with pain in the contralateral heel
of >4 on the visual analog scale was excluded from the study.
Patients filled out a Short Form-36 (SF-36) questionnaire 59 before treatment and at three months and twelve
months after treatment. All patients also were given specific
self-assessment questions regarding pain at rest, pain with activity throughout the day, level of participation in recreational
activities, and the ability to work.
All patients had radiographs of the heel made in three
views during the pretreatment evaluation, at three months after treatment, and at the final follow-up evaluation at one
year. The presence or absence of a plantar heel spur was documented. The presence of intraosseous lesions, such as a calcaneal cyst or subtalar arthritis, was exclusionary.
The blinded investigator (evaluator) used a pressure
sensor (dolorimeter) to document objectively the amount of
pressure (lb/in2) that, when applied to the site of maximum
tenderness, elicited from the study subject a subjective baseline visual analog scale response duplicating maximum daily
pain. At each subsequent posttreatment evaluation, the same
baseline dolorimeter pressure was applied and the patient was
asked to requantify the current amount of pain using the visual analog scale response. This method ensured consistency
of the objective pressure evaluation, while allowing for the
subjective evaluation, by the patient, of changes in the amount
of pain perceived at the time of follow-up.
Patients were treated in an outpatient surgical center.
Prior to ankle-block anesthesia, the point of maximum plantar surface tenderness was demarcated (targeted) with a surgical marking pen. The involved leg was draped from the direct
view of the patient. Ear protection devices were used by the
study subject and all involved personnel. Patients received either a complete ankle-block anesthesia with lidocaine (the
treatment group) or three 1-mL subcutaneous injections of
lidocaine (the placebo group) prior to the application of shock
waves. The shock-wave treatments were applied with use of
the OssaTron device. Standard ultrasound gel was applied to
the heel for transcutaneous conduction of the shock waves
from the OssaTron into the heel tissues. The device was adjusted to maximize the focused treatment wave (f2) into the
plantar fascia60. Each study subject assigned to active treatment received 100 graded shocks (14 to 18 kV; 0.12 to 0.22
mJ/mm2) to assess the effectiveness of anesthesia, followed by
1400 shocks at 18 kV (0.22 mJ/mm2) for a total of 1500 shocks,
all of which were applied at two per second (2 Hz). The total
energy delivered was 324.25 J. The treating physician continually manipulated the heel against the treatment head throughout the shock-wave applications. Shock waves thus were
applied to the maximum pain site as well as an area in a 1-cm
radius surrounding it.
For the patients assigned to placebo treatment, a styrofoam block was placed against the treatment head to absorb
the shock waves by the presence of the multiple air cavities. In
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addition, a fluid-filled intravenous bag was placed between the
styrofoam block and the subject’s heel to mimic the waterfilled treatment head. Patients who received a placebo treatment did not have any coupling gel (ultrasound gel) applied to
the heel. Placebo patients also had 1500 shocks “delivered” according to the aforementioned gradation protocol, effectively
duplicating the duration and noise of an active treatment. Patients who received the placebo treatment and patients who
received the active treatment were kept apart in the recovery
room to avoid any discussions and comparisons about what
occurred in the surgical suite.
All patients underwent evaluations within forty-eight
hours following treatment and at one, two, three, six, nine, and
twelve months. In both phase 1 and phase 2, an initial success
or failure status was assigned on the basis of the subjective and
objective findings three months after the initial treatment. This
three-month interval was selected on the basis of the expectation that some or all of the healing process most likely would
be evident at that time. Subsequently, patients either were followed to one year without additional intervention or received
additional treatment followed by periodic evaluations until
one year following the additional treatment. Patients were encouraged to continue follow-up beyond one year.
At three and twelve months, patients were assigned a
success or failure status according to each of four predetermined primary criteria. (1) On the investigator assessment of
pain, the patient had to have a minimum improvement of
50% over the dolorimeter-induced baseline pain score, with a
required score of ≤4 on the visual analog scale. (2) On the patient self-assessment of pain on first walking in the morning,
success required a minimum improvement of 50% over the
pretreatment baseline and a visual analog scale score of ≤4. (3)
On the patient self-assessment of activity with regard to the
distance and time that he or she was able to walk without heel
pain, the patient had to demonstrate an improvement of ≥1
point on a 5-point scale or had to maintain a 0 or 1 baseline
level (no pain or minimal pain). (4) With regard to the use of
pain medications, prescription analgesics were not given after
treatment. Self-treatment with over-the-counter analgesics or
anti-inflammatory medications was documented with a medication log returned at each evaluation. Success required that
the patient had not taken any such medication (even for a reason other than pain in the treated heel) between ten and
twelve weeks after treatment.
Each patient in the randomized group unequivocally
had to meet all four success criteria to attain an overall status
assignment of success.
Patients who were assigned a failure status at three
months were informed that they could (1) withdraw from the
study to pursue alternative treatment modalities or (2) continue in the study by trying an additional active treatment as
allowed by the study protocol. All evaluations of retreatment
or crossover from placebo to active treatment were done according to the same protocol as for the primary treatmentplacebo study arm.
The patients who elected to receive an additional treat-
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ment or treatments were classified arbitrarily as having a failure of the initial treatment. All patients receiving additional
treatment were followed according to the same protocol (with
evaluations at one, two, three, six, nine, and twelve months)
after the last applied shock-wave treatment.
If patients did not complete the twelve-month followup protocol, efforts were made to encourage compliance. Any
patient who failed to respond to these efforts was classified as
a failure in the outcome assessment.
Patient acceptance into the study, data collection, and
analysis were further blinded. At each center, a research assistant collected questionnaire data (subject self-assessments and
SF-36) independently of the evaluating physician. Individual
centers were not allowed to communicate with each other.
Data from all centers were sent to an independent organization, M2 and Associates, for composite compilation and initial
analyses. Final data sets and analyses were then sent to an outside statistician, Stat-Tech Services, to validate the results.
Univariate analyses were performed with use of the
Pearson chi-square statistic. Multiple logistic regression was
used to test jointly the explanatory variables that were significant in the univariate analyses. The adjusted odds ratios were
presented with the respective 95% confidence intervals. Significance was considered at a two-tailed level of <0.05.
The study sample size was obtained on the basis of the
need to collect sufficient safety information. The original efficacy sample size was calculated on the basis of an assumed response of 70% in the active treatment arm and 30% in the
placebo arm, which was smaller than the sample size required
for adequate safety information. Additional subjects were added
after the study sample size was reached in order to allow continued patient access and obtain additional safety information.
The primary efficacy analysis was based on the success
status at three months. The p value for the inferential evaluation of the null hypothesis of no treatment effect was obtained
with use of a likelihood ratio test controlling for study site.
The test statistic was obtained by evaluating the difference in
log-likelihood for the logistic model including the study site
and treatment and the logistic model including only the study
site. The Pearson chi-square test also was used to evaluate the
null hypothesis that there was no association between treatment and response at three months.
To investigate the durability of the response through six
months and one year, the time-to-failure after the initial treatment was compared with use of Kaplan-Meier methodology,
and inference was based on the log-rank statistic. Substantially
more follow-up data were available to support this analysis
than were available for the three-month analysis at the time of
the initial Food and Drug Administration submission. The
proportion of six-month and one-year responders was compared, with use of a Pearson chi-square test, for all subjects
who had six months of follow-up data. A two-tailed Fisher exact test was used to compare the distribution of successful outcomes at three months for the patients who had retreatment
with electrohydraulic shock waves and the patients who initially had the placebo treatment. Secondary efficacy measures
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of the visual analog scale scores for pain were summarized at
each visit through six months. The six-month and one-year
time-points included only subjects who were responders at
three months. The hypothesis of no treatment difference in
the mean percentage change from baseline was evaluated with
use of a t test assuming equal variance.
Selected demographic and baseline characteristics were
assessed for homogeneity in the subject population across
sites and treatment groups. The assessment of homogeneity
was used to assist in the interpretation of the efficacy and
safety analyses. For categorical variables, a logistic modeling
approach was used. For continuous variables, a general linear
modeling approach was used and inference was based on p
values associated with the type-III sums of squares.
Deviations from planned analyses included use of an
additional Pearson chi-square test to compare the proportion
of subjects with a successful outcome at six months. No further confidence intervals were calculated, except for the 95%
confidence interval of the relative risk for success at three
months. Testing comparing the visual analog scale scores for
the patients who had retreatment with electrohydraulic shock
waves and the patients who were initially treated with placebo
was not performed.
Results
wenty patients were enrolled in the phase-1 study (Fig. 1).
The treating and evaluating physician was the same individual, and all patients knew that they received active extracorporeal shock-wave treatment. Seventeen patients (85%)
had substantial improvement or complete relief of pretreatment symptoms at three months. Three patients were not satisfied with the results at three months and chose a second
treatment. Two of the three had symptomatic improvement,
whereas one continued to have no improvement. All twenty
patients were followed to one year, with a good-to-excellent
result maintained at one year in nineteen54. These nineteen patients reported continued relief of symptoms for sixty-five to
sixty-eight months later, and none had a recurrence of symptoms. The single patient who had no symptomatic improvement continued to have chronic pain.
Phase 2 involved 344 patients, comprising 293 randomized and fifty-one nonrandomized study subjects (Figs. 2 and
3). This patient population was predominantly female (66.3%).
The mean age of the subjects at the time of enrollment was
48.6 years (range, nineteen to seventy-nine years; median
[and standard deviation], 49 ± 11.3 years). Age was not significantly associated with the three-month outcome (p = 0.138).
Gender, ethnicity, and pretreatment osteoarthritis in other
joints, such as the knee or the hip, were not significantly associated with success or failure.
Of the 148 randomized patients who had an active treatment initially, 144 returned for all evaluations up to three
months and eighty-nine continued to twelve months. Of the
145 randomized patients who initially received a placebo, 141
returned for evaluations at three months and sixty-four continued to twelve months. Of the fifty-one nonrandomized pa-
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tients, forty-seven returned for evaluations at three months
and thirty-six continued to twelve months. Altogether 189
phase-2 patients (55%) cooperated in follow-up to at least one
year following the initial treatment.
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Duration of Symptoms
All patient groups were similar with respect to the mean duration of symptoms prior to shock-wave or placebo treatment.
The duration of symptoms was significantly associated with

Fig. 1

Flowchart of phase-1 patients.
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Fig. 2

Flowchart of randomized phase-2 patients.

success (p = 0.001). Adjusting for the duration of symptoms
affected the overall significance of the association between
treatment and success (p = 0.004). The analysis divided the
population into patients with a shorter duration of pain (less

than or equal to the median duration) and those with a
greater duration of pain (more than the median duration). Patients with a shorter duration of symptoms had higher response rates, and the absolute difference in the success rates
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between the two patient groups was similar in magnitude. The
difference in treatment success rates was 13% (52% for the active treatment group compared with 39% for the placebo group)
for the patients with a shorter duration of pain and 20% (40%
for the active treatment group compared with 20% for the
placebo group) for the patients with a longer duration.
Investigator Heel-Pain Assessment
All treatment groups had comparable baseline pain scores
(Table I). Evaluation of the investigator assessment of heel
pain at four, eight, and twelve weeks indicated significant
treatment effects as early as the four-week visit. The percent-
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age change (improvement) in investigator assessment of heel
pain at four, eight, and twelve weeks was 41%, 49%, and
59%, respectively, for active treatment subjects compared
with 27%, 32%, and 43%, respectively, for placebo treatment
subjects. The p values for the comparisons of active treatment versus placebo at these visits were 0.018, 0.001, and
0.002, respectively. This dolorimeter-based visual analog
scale measurement at three months was the most sensitive
measure comparing patients who had received active treatment with those who had been randomized to treatment
with a placebo (p = 0.002). This sensitivity was maintained
at twelve months (p = 0.005).

Fig. 3

Flowchart of nonrandomized phase-2 patients.
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TABLE I Physician Assessment of Heel Pain*
Phase 2
Phase 1

Treated

Placebo (No Cross Over)

Placebo (Cross Over)

Nonrandomized

Baseline (n = 364)

7.95

7.80

7.99

7.67

7.83

12 weeks (n = 352)

2.95

3.23

4.52

2.50

2.01

1 year (n = 209)

1.67

1.87

5.13

1.73

1.39

*The values are given as the mean score on the visual analog scale.

TABLE II Patient Self-Assessment of Morning Heel Pain*
Phase 2
Phase 1

Treated

Placebo

Nonrandomized

Baseline (n = 364)

7.83

8.08

8.14

6.85

12 weeks (n = 352)

3.17

3.43

4.28

2.36

1 year (n = 209)

1.34

1.41

3.54

1.27

*The values are given as the mean score on the visual analog scale.

Subject Self-Assessment of Morning Heel Pain
Baseline values were comparable (Table II). For the patient
self-assessment of morning heel pain, the mean score at four,
eight, and twelve weeks improved 45%, 50%, and 58%, respectively, for the subjects who had active treatment and 31%,
39%, and 47%, respectively, for the subjects who had placebo
treatment. The p values for the comparisons of active treatment and placebo effects at these visits were 0.002, 0.021, and
0.014, respectively. At twelve months, this difference was
maintained (p = 0.015).
Subject Self-Assessment of Activity-Related Pain
Baseline values were comparable (Table III). For the patient
self-assessment of pain with activity, the mean score at four,
eight, and twelve weeks improved 40%, 53%, and 51%, respectively, for patients who had active treatment and 29%,
32%, and 47%, respectively, for subjects who had placebo
treatment. The p values for the comparisons of active treatment and placebo effects at these visits were 0.024, 0.077, and
0.059, respectively. By twelve months, however, no difference
in subjective self-assessment of activity-related pain persisted
between the two groups.
Use of Pain Medications
This parameter had the least sensitivity to differentiate between actively treated patients and those who received the placebo as success levels in both groups were nearly identical.
Furthermore, over 70% of the patients took medications for
pain in another body region than the treated heel.
Repeat Procedures
In phase 2, forty-seven (61%) of the seventy-seven patients
who had active treatment and were assigned to a failure status
at twelve weeks chose to have retreatment, whereas eighty-

four (85%) of ninety-nine placebo-treated patients with a failure status at twelve weeks chose to undergo an active extracorporeal shock-wave treatment and nineteen had a second active
treatment. In the nonrandomized cohort, eleven (23%) of
forty-seven patients chose a second treatment. A total of 370
active extracorporeal shock-wave treatments were performed
in randomized and nonrandomized subjects. The difference
between the randomized, actively treated patients and the
placebo-treated patients with respect to the selection of a second treatment was significant (p = 0.003).
At three months, twenty-two of forty-two patients who
were initially actively treated and received a second active
treatment attained success. This success was maintained in
eighteen of the twenty-two patients at one year. Three months
after seventy-eight placebo-treated patients had crossover
treatment, thirty-six attained success. At one year, thirty-nine
patients were lost to follow-up. Of the remaining thirty-six patients, thirty had a successful outcome. Three months after a
repeat procedure, six of eleven nonrandomized subjects had a
successful outcome and six of eight had a successful outcome
at one year.
Complications
There were no complications in the phase-1 patients. The
most frequent phase-2-related complications in all groups were
pain after treatment and mild neurologic symptoms (numbness or dysesthesia) principally related to the ankle-block
anesthesia. All patients had complete resolution of the posttreatment neurologic symptoms by the three-month evaluation, and no patient had neurologic complaints at one year.
Rates of Treatment Success for Randomized Patients
Of the 144 phase-2 patients who were randomized to active
treatment, 47% met all four success criteria at three months
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TABLE III Patient Self-Assessment of Pain During Activity*
Phase 2
Phase 1

Treated

Placebo

Nonrandomized

Baseline (n = 364)

3.18

3.49

3.53

2.63

12 weeks (n = 352)

0.91

1.72

1.88

0.85

1 year (n = 209)

0.61

0.83

1.56

0.63

*The values are given as the mean score on the visual analog scale.

TABLE IV Summary of Data on 289 Patients Treated During the Food and Drug Administration Clinical Trial
Outcome*
Excellent

Good

Fair

Poor

Phase 1

19

—

1

—

Phase-2 treated

67

37

21

19

Phase-2 crossover treated

36

24

8

10

Phase-2 nonrandomized

25

14

5

3

147

75

35

32

Total†

61

*The outcome was evaluated according to the criteria described by Roles and Maudsley , with an excellent outcome indicating that all four
criteria for success were met; good, that two or three of the four criteria were met; fair, that one of the four criteria was met; and poor, that
none of the four criteria was met. †A total of 222 patients had a good or excellent result, and sixty-seven patients had a fair or poor result.

compared with 30% of the 141 subjects who received placebo
treatment (p = 0.008). Of the fifty-one nonrandomized patients, 67% met all four success criteria. Of the eighty-four patients who had been randomized to placebo treatment, failed
to meet the four success criteria, and subsequently elected to
have an active treatment, 43% subsequently achieved a success
at three months. The time to treatment failure was evaluated
starting at three months and followed through to twelve
months. A significant difference was found when patients who
had one or more treatments (including crossover treatments)
with success were compared with patients (actively treated
and placebo-treated) who were rated as having a failure (logrank test, chi-square = 9.68; p = 0.0019).
The primary efficacy comparison for success of all four
components of efficacy at three months indicated a robust
treatment effect (p = 0.003). Accordingly, the relative risk for
success at three months (active treatment relative to placebo)
was 1.56 (95% confidence interval, 1.15 to 2.13), implying a
>50% increase in the chance of success at three months with
active treatment compared with placebo.
In the phase-2 patients, the rate of success maintained at
twelve months was 93% for those initially treated actively, 83%
for those who crossed over from initial placebo treatment, and
93% for those who were not randomized. In contrast, only
twenty-five (18%) of the 141 patients who received the placebo
and chose no subsequent treatment at three months had a success at twelve months. At twelve months, the differences between the actively treated patients and the placebo-treated
patients showed a continuing significance (p = 0.002). Thirtyfour patients subsequently were followed between twelve and

twenty-seven months, and all maintained the successful results. The overall maintenance of a successful outcome was
found to be significant (Fisher exact test, p = 0.040).
Analysis of All Treated Patients
Although only the randomized patients were used for the initial three-month and final one-year statistical analyses submitted to the Food and Drug Administration, the results in all
patients were subsequently assessed in a clinically relevant
manner with use of a grading system similar to one commonly
used in most published European musculoskeletal shock-wave
outcome studies61. Patients who had initial visual analog scale
scores (in the first three outcome assessment categories) of >8
frequently met the criterion of 50% improvement, but they
failed to have a visual analog scale score of ≤4. All 289 phase-1
and 2 patients who received one or two actual shock-wave
treatments were grouped together and were rated as having an
excellent result if all four success criteria were met, a good result if two or three of the four success criteria were met, a fair
result if one of the four success criteria were met, or a poor result if none of the four success criteria were met.
With use of this grading system, 147 (50.9%) of 289 patients had an excellent result and seventy-five (26%) had a good
result (Table IV), for a combined total of 222 patients (76.8%)
in whom the result was considered a success, even when pain
relief was not complete in one of the outcome categories.
Discussion
hronic heel pain that adversely affects employment or lifestyle is a common complaint. A heel spur is evident in
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50% to 60% of patients having a diagnosis of heel pain. In one
study, electrohydraulic shock waves delivered at the energy
level used for plantar fasciitis (18 to 20 kV; 0.22 to 0.27 mJ/
mm2) caused no change in the heel spur when one was present
nor did the presence or absence of an inferior heel spur affect
the likelihood of a positive response62.
The initial treatment of proximal plantar fasciitis should
be conservative (nonsurgical), an approach that may be successful in as many as 90% of patients by providing substantial,
if not complete, relief of the symptoms63. However, there is no
consensus for a specific treatment protocol, particularly when
symptoms last for more than three months.
Evaluations of the nonoperative methods for treating
chronic plantar fasciitis have been difficult to assess statistically, since many protocols have included multiple and variable nonoperative regimens within the same study, and few
nonoperative treatments have been analyzed with randomized
controlled studies63. Martin et al. reviewed numerous studies
on nonoperative treatment and showed a wide variation in
acceptable outcomes, ranging from 44% to 82% (average, 60.3%)
of patients who had complete relief of heel pain64. Interestingly, in that study, only 51% of the patients were completely
asymptomatic following treatment, whereas 82% were satisfied with the final outcome relative to the amount of residual
pain64. We found similar outcome perceptions and satisfaction levels by the patients who received shock-wave treatment;
complete pain relief was not needed for patient satisfaction
with the eventual outcome.
Of interest was the lower than expected rate of retreatment in the active treatment arm of study. The study was designed on the assumption that the majority of subjects who
failed to respond to the primary treatment would elect to have
a second treatment. However, forty-seven (61%) of the seventy-seven treated subjects who failed to meet all four success
criteria chose retreatment compared with eighty-four (85%)
of the ninety-nine patients who failed the placebo treatment.
This observation suggests that many subjects who were assigned
a final “fail” status (less than four of the four criteria for success
were met) may have been sufficiently satisfied with the outcome that they did not want a second treatment.
When such noninvasive methods fail to achieve relief
in a reasonable period of time, surgery frequently is recommended. A recent study found that patients undergoing electrohydraulic high-energy shock-wave application and patients
undergoing percutaneous partial fasciotomy had comparable
outcomes65. However, the former group (patients who had extracorporeal shock waves) had a more rapid return to the activities of work and daily living.
The technology of applying shock waves to the heel is
similar to that used for lithotripsy. Several devices have been
designed specifically for the treatment of musculoskeletal conditions. This is necessary since the energy levels, the focused
volume of the energy ellipsoid (f2), the central size of the
maximum energy level within the ellipsoid, and the depth of
penetration used in lithotripsy are different from those considered safe and effective for musculoskeletal tissues that are
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not as deeply situated as the kidneys and ureters. These musculoskeletal devices generate and focus the shock waves by one
of three basic methods—electrohydraulic, electromagnetic, or
piezoelectric60. The differences in shock-wave energy to the
target tissue relate specifically to the method of generation of
the shock wave, the size and volume of the f2 ellipsoid, and the
depth of energy penetration. These factors may result in significant differences in the potential clinical efficacy2,60. Comparison studies with lithotriptors (for renal stones only) have
described the electrohydraulic method as being more clinically effective in stone fragmentation compared with electromagnetic or piezoelectric devices66. The machine used for the
current musculoskeletal studies employed electrohydraulic
shock-wave generation and was the first shock-wave device
approved by the Food and Drug Administration for any
musculoskeletal indications53. Since direct comparison studies of machines have not been done, there is no information
concerning the relative efficacy of one method of shock-wave
generation over any other for specific musculoskeletal tissue
applications60.
Electrohydraulic application is based on one treatment
in most patients, whereas electromagnetic and piezoelectric
devices, as described in most European-based publications,
routinely use multiple (three to six) treatments1,2. Buchbinder
et al. assessed a low-energy electromagnetic device in a randomized, double-blind, placebo-controlled study with use of
three treatments49. They found no differences between the patients who received active treatment and those who received
the placebo. This observation suggested that the overall efficacy of low-energy, multiple shock-wave treatments for musculoskeletal applications was questionable. However, such a
generalization was inappropriate because of limitations of that
particular study (the patients were treated as early as six weeks
after symptom onset, actual shock waves were delivered to
placebo-treated patients, and variable numbers of shocks [mJ/
mm2 and total energy (Joules)] per patient were used) compared with other studies. Furthermore, patients received no
specific physical examinations before and after treatment, and
no orthopaedist was involved in the study. A “trained technician” delivered the treatment after a radiologist focused the
device with use of ultrasound. In the current study, patients
had to have had symptoms for a minimum of six months, all
patients received exactly the same energy levels, shock waves
were not delivered to placebo patients, and trained orthopaedists actively participated in the evaluation and treatment of
the patients. When the Food and Drug Administration approved the OssaTron device, one stipulation was that treatment should be administered only by an appropriately trained
and certified physician or podiatrist.
Other studies on low-energy electromagnetic shock
waves in which patients received the same dosage and those
treated with a placebo received no shock waves, with delivery in
a transverse direction, also showed no effective difference between the actively treated patients and the patients who received the placebo 50,51. Those studies (compared with the
present study on high-energy electrohydraulic shock waves) sug-
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gested that there are different tissue responses to shock waves
contingent upon the method of generation (electrohydraulic or
electromagnetic), the level of energy applied, or the direction of
delivery (perpendicular to the plantar surface or transverse).
Low-energy electromagnetic and piezoelectric devices
have an adjunct ultrasound device that must be used to focus
f2 because the low-energy shock waves are delivered in a medial-to-lateral direction, rather than perpendicular to the
plantar surface. This technique delivers shock waves to the
thinnest portion of the fascia, which is done to minimize
shock-wave impaction against the calcaneus, thus avoiding
pain stimulation and the need for anesthesia. This technique
requires additional expertise in ultrasound imaging by the
treating physician. With transverse delivery, the foot is held in
a fixed position. Accordingly, only a small section of the fascia
is impacted by the shock waves. In contrast, the electrohydraulic shock waves are administered through the plantar surface (a wider surface area), targeting the point of maximal
pain, and the foot is continually manipulated to treat an area 2
cm in diameter around the predetermined focal point of maximal pain. Some of the shock waves strike the calcaneus and
bone and are reflected back into the involved fascia, potentially increasing the total effect of each shock wave.
One study stated that the low-energy treatment was
considered “unpleasant by all patients.”32 Treatment with highenergy shock waves, particularly those generated electrohydraulically, requires some type of anesthetic agent. In our
study, patients receiving the actual high-energy shock waves
were administered an ankle block. Since the approval of the
device by the Food and Drug Administration, we have also
used conscious sedation. This anesthetic technique also allows the treatment of both heels when appropriate levels of
chronic fascial pain are present bilaterally67.
Rompe et al. performed several studies on the treatment
of plantar fasciitis with shock waves4,32,39,43. Those studies all
used electromagnetically generated shock waves, involved
multiple treatments, and varied considerably with respect to
the treatment protocols. All outcome evaluations emphasized
subjective improvement, rather than complete relief of heel
pain, and used outcome criteria that were much less restrictive
than those used in our study. In one study, Rompe et al. recently reported on patients who had a successful outcome five
years after treatment with low-energy extracorporeal shock
waves43. Hammer et al. reported on forty-four patients with
chronic plantar fasciitis who were treated with piezoelectric
shock-wave generation42. There were no control patients. In
twenty-four of forty-four patients (55%), the visual analog
scale improved; however, only thirteen patients (30%) rated
the outcome as completely successful.
The mechanism of shock-wave action in soft tissues
(tendon and fascia) is still under investigation. Rompe et al.
showed no tendon cellular damage in a rabbit model with use
of energy levels normally applied clinically for the treatment
of plantar fasciitis10,11. They demonstrated neovascular proliferation as did Wang et al.14,22. When shock waves are applied to
bone (at a much greater energy level and number of shocks),
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microfractures and osteocyte damage occur, followed by a
proliferation of osteoblasts and elaboration of bone1,2,4,17,20,23-26.
A similar microdisruption of the thickened plantar fascial origin probably occurs, resulting in an inflammatory and softtissue reparative response2,10,14.
This study presents robust evidence of a treatment effect.
The primary efficacy end point of success at three months and
the analysis of sustained response were both highly significant
(p < 0.01). Analyses of the long-term (one-year) response supported a continuing treatment difference. Hence, there is ample evidence that electrohydraulically generated high-energy
transcutaneous shock-wave treatment is an effective treatment
of heel pain due to chronic plantar fasciitis when compared
with placebo. We believe that our data support the use of electrohydraulic high-energy shock-wave treatment before consideration of any open or endoscopic surgical treatment.
Appendix
A table showing the complete inclusion-exclusion criteria is available with the electronic versions of this article,
on our web site at jbjs.org (go to the article citation and click
on “Supplementary Material”) and on our quarterly CDROM (call our subscription department, at 781-449-9780, to
order the CD-ROM). 
NOTE: The authors acknowledge the multiple physicians and support staff at the participating
study sites, including Dirk Asherman, MD, Judith Baumhauer, MD, James Beskin, MD, Raj
Bholé, MD, Victor Brown, DO, Roger Castillo, PA, Thomas Chi, MD, Mitchell Cooper, MD,
Michael Coughlin, MD, Greg Crawley, MD, G. Lee Cross, MD, Jeffrey DeLoach, DO, Benedict F.
DiGiovanni, MD, Russell Ellis, MD, Anthony Furguson, MD, Timothy M. Ganey, PhD, Anthony
Gatti, DPM, Jerome J. Gilden, MD, John S. Gould, MD, Ninoo Hollis, MD, Juha Jaakkola, MD,
Perry Julian, DPM, Ashok Kumar, MD, Gary Lourie, MD, Gregory Lee, MD, John Marymont, MD,
Troy Maxwell, James McWilliams, MD, Deborah Nawoczenski, PT, PhD, Vinood Panchbahvi, Preti
Patel, Tim Petsche, MD, Douglas Powell, MD, William Ricci, MD, Felix Rodriguez del Rio, MD,
Sally Rudicel, MD, Harlan Selesnick, MD, Michael Shutte, MD, Pamela Smith, RN, Brian Terry,
MD, Davis Thornbury, MD, Saul G. Trevino, MD, Kevin Varner, MD, James Voglino, MD, Peter
Weiman, and Sharrona Williams, MD.

John A. Ogden, MD
Skeletal Educational Association, 3435 Habersham Road N.W., Atlanta,
GA 30305. E-mail address: orthozap@aol.com
Richard G. Alvarez, MD
725 Glenwood Drive, Suite E-884, Chattanooga, TN 37404
Richard L. Levitt, MD
1150 Campo Sano Avenue, Suite 301, Coral Gables, FL 33146
Jeffrey E. Johnson, MD
Department of Orthopaedics, Washington University School of Medicine, 660 South Euclid, Box 8233, St. Louis, MO 63110
Marie E. Marlow, RN
719 A Street N.E., Washington, DC 20002
In support of their research or preparation of this manuscript, one or
more of the authors received grants or outside funding from HealthTronics Surgical Services, Marietta, Georgia; High Medical Technologies, Lengwil, Switzerland; and the Skeletal Educational Association, Atlanta,
Georgia. In addition, one or more of the authors received payments or
other benefits or a commitment or agreement to provide such benefits
from a commercial entity (HealthTronics). Also, a commercial entity
(HealthTronics) paid or directed, or agreed to pay or direct, benefits to a
research fund, foundation, educational institution, or other charitable or
nonprofit organization with which the authors are affiliated or associated.


THE JOUR NAL OF BONE & JOINT SURGER Y · JBJS.ORG
VO L U M E 86-A · N U M B E R 10 · O C T O B E R 2004

E L E C T RO HYD R A U L I C H I G H -E N E R G Y S H O C K -WAVE
TRE A T M E N T F O R C H RO N I C P L A N T A R F A S C I I T I S

References
1. Heller KD, Niethard FU. [Using extracorporeal shockwave therapy in orthopedics—a meta-analysis.] Z Orthop Ihre Grenzgeb. 1998;136:390-401. German.

genic transcription factor HIF-1 alpha and VEGF-A expression in shock wavestimulated osteoblasts. J Biol Chem. 2004;279:10331-7.

2. Ogden JA, Alvarez RG, Levitt R, Marlow M. Shock wave therapy (Orthotripsy)
in musculoskeletal disorders. Clin Orthop. 2001;387:22-40.

25. Martini L, Fini M, Giavaresi G, Torricelli P, de Pretto M, Rimondini L, Giardino R. Primary osteoblasts response to shock wave therapy using different
parameters. Artif Cells Blood Substit Immobil Biotechnol. 2003;31:449-66.

3. Rompe JD, Buch M, Gerdesmeyer L, Haake M, Loew M, Maier M, Heine J.
[Musculoskeletal shock wave therapy—current database of clinical research.] Z Orthop Ihre Grenzgeb. 2002;140:267-74. German.
4. Rompe JD. Shock wave applications in musculoskeletal disorders. New York:
Thieme Medical Publishers; 2002. p 33-6.
5. Pan PJ, Chou CL, Chiou HJ, Ma HL, Lee HC, Chan RC. Extracorporeal shock
wave therapy for chronic calcific tendinitis of the shoulders: a functional and
sonographic study. Arch Phys Med Rehabil. 2003;84:988-93.
6. Wang CJ, Yang KD, Wang FS, Chen HH, Wang JW. Shock wave therapy for
calcific tendinitis of the shoulder: a prospective clinical study with a two-year
follow-up. Am J Sports Med. 2003;31:425-30.
7. Gerdesmeyer L, Wagenpfeil S, Haake M, Maier M, Loew M, Wörtler K,
Lampe R, Seil R, Handle G, Gassel S, Rompe JD. Extracorporeal shock wave
therapy for the treatment of chronic calcifying tendonitis of the rotator cuff: a
randomized controlled trial. JAMA. 2003;290:2573-80.

26. Chen YJ, Kuo YR, Yang KD, Wang CJ, Huang HC, Wang FS. Shock wave application enhances pertussis toxin protein-sensitive bone formation of segmental femoral defect in rats. J Bone Miner Res. 2003;18:2169-79.
27. Buch M, Siebert W. Shockwave treatment for heel pain syndrome—a prospective investigation. In: Coombs R, Schaden W, Zhou SSH, editors. Musculoskeletal shockwave therapy. London: Greenwich Medical Media; 2000. p 73-7.
28. Hsu RW, Hsu WH, Tai CL, Lee KF. Effect of shock-wave therapy on patellar
tendinopathy in a rabbit model. J Orthop Res. 2004;22:221-7.
29. Hammer DS, Rupp S, Kreutz A, Pape D, Kohn D, Seil R. Extracorporeal
shockwave therapy (ESWT) in patients with chronic proximal plantar fasciitis.
Foot Ankle Int. 2002;23:309-13.
30. Hammer DS, Rupp S, Ensslin S, Kohn D, Seil R. Extracorporeal shock wave
therapy in patients with tennis elbow and painful heel. Arch Orthop Trauma
Surg. 2000;120:304-7.

8. Peers KH, Lysens RJ, Brys P, Bellemans J. Cross-sectional outcome analysis
of athletes with chronic patellar tendinopathy treated surgically and by extracorporeal shock wave therapy. Clin J Sport Med. 2003;13:79-83.

31. Krischek O, Rompe JD, Herbsthofer B, Nafe B. [Symptomatic low-energy
shockwave therapy in heel pain and radiologically detected plantar heel spur.]
Z Orthop Ihre Grenzgeb. 1998;136:169-74. German.

9. Ludwig J, Lauber S, Lauber HJ, Dreisilker U, Raedel R, Hotzinger H. Highenergy shock wave treatment of femoral head necrosis in adults. Clin Orthop.
2001;387:119-26.

32. Rompe JD, Küllmer K, Riehle HM, Herbsthofer B, Eckardt A, Bürger R, Nafe
B, Eysel P. Effectivenss of low-energy extracorporal shock waves for chronic
plantar fasciitis. Foot Ankle Surg. 1996;2:215-21.

10. Rompe JD, Kirkpatrick CJ, Küllmer K, Schwitalle M, Krischek O. Doserelated effects of shock waves on rabbit tendo Achilles. A sonographic and
histological study. J Bone Joint Surg Br. 1998;80:546-52.
11. Rompe JD. [Shockwave therapy: therapeutic effects in a speculative mechanism.] Z Orthop Ihre Grenzgeb. 1996;134:Oa13-9. German.
12. Haake M, Wessel C, Wilke A. [Effects of extracorporeal shock waves (ESW)
on human bone marrow cell cultures.] Biomed Tech (Berl). 1999;44:278-82.
German.

33. Schõellner C, Riedel C, Schwitalle M, Rompe JD, Heine J. Shockwave treatment for plantar heel pain. In: Coombs R, Schaden W, Zhou SSH, editors.
Musculoskeletal shockwave therapy. London: Greenwich Medical Media;
2000. p 53-9.
34. Wang CJ, Chen LM, Chen WS, Chen HS. Heel spurs. In: Coombs R, Schaden
W, Zhou SSH, editors. Musculoskeletal shockwave therapy. London: Greenwich Medical Media; 2000. p 61-9.
35. Perlick L, Boxberg W, Giebel G. [High energy shock wave treatment of the
painful heel spur.] Unfallchirurg. 1998;101:914-8. German.

13. Lin JH, Wang MX, Wei A, Zhu W, Diwan AD, Murrell GA. Temporal expression of nitric oxide synthase isoforms in healing Achilles tendon. J Orthop
Res. 2001;19:136-42.

36. Wang CJ, Chen HS, Chen WS, Chen LM. Treatment of painful heels using extracorporeal shock wave. J Formos Med Assoc. 2000;99:580-3.

14. Wang CJ, Huang HY, Pai CH. Shock wave-enhanced neovascularization at
the tendon-bone junction: an experiment in dogs. J Foot Ankle Surg. 2002;41:
16-22.

37. Maier M, Steinborn M, Schmitz C, Stabler A, Kohler S, Pfahler M, Dürr HR,
Refior HJ. Extracorporeal shock wave application for chronic plantar fasciitis
associated with heel spurs: prediction of outcome by magnetic resonance imaging. J Rheumatol. 2000;27:2455-62.

15. Orhan Z, Alper M, Akman Y, Yavuz O, Yalciner A. An experimental study on
the application of extracorporeal shock waves in the treatment of tendon injuries: preliminary report. J Orthop Sci. 2001;6:566-70.
16. Takahashi N, Wada Y, Ohtori S, Saisu T, Moriya H. Application of shock
waves to rat skin decreases calcitonin gene-related peptide immunoreactivity in dorsal root ganglion neurons. Auton Neurosci. 2003;107:81-4.
17. Narasaki K, Shimizu H, Beppu M, Aoki H, Takagi M, Takashi M. Effect of extracorporeal shock waves on callus formation during bone lengthening. J Orthop Sci. 2003;8:474-81.
18. Martini L, Giavaresi G, Fini M, Torricelli P, de Pretto M, Schaden W, Giardino R. Effect of extracorporeal shock wave therapy on osteoblastlike cells.
Clin Orthop. 2003;413:269-80.
19. Dorotka R, Kubista B, Schatz KD, Trieb K. Effects of extracorporeal shock
waves on human articular chondrocytes and ovine bone marrow stromal cells
in vitro. Arch Orthop Trauma Surg. 2003;123:345-8.
20. Hsu RW, Tai CL, Chen CY, Hsu WH, Hsueh S. Enhancing mechanical strength
during early fracture healing via shockwave treatment: an animal study. Clin
Biomech (Bristol, Avon). 2003;18:S33-9.
21. Maier M, Averbeck B, Milz S, Refior HJ, Schmitz C. Substance P and prostaglandin E2 release after shock wave application to the rabbit femur. Clin Orthop. 2003;406:237-45.

38. Böddeker R, Schäfer H, Haake M. Extracorporeal shockwave therapy (ESWT)
in the treatment of plantar fasciitis—a biometrical review. Clin Rheumatol.
2001;20:324-30.
39. Rompe JD, Hopf C, Nafe B, Bürger R. Low-energy extracorporeal shock wave
therapy for painful heel: a prospective controlled single-blind study. Arch Orthop Trauma Surg. 1996;115:75-9.
40. Chen HS, Chen LM, Huang TW. Treatment of painful heel syndrome with
shock waves. Clin Orthop. 2001;387:41-6.
41. Wang CJ, Chen HS, Huang TW. Shockwave therapy for patients with plantar
fasciitis: a one-year follow-up study. Foot Ankle Int. 2002;23:204-7.
42. Hammer DS, Adam F, Kreutz A, Kohn D, Seil R. Extracorporeal shock wave
therapy (ESWT) in patients with chronic proximal plantar fasciitis: a 2-year
follow-up. Foot Ankle Int. 2003;24:823-8.
43. Rompe JD, Schoellner C, Nafe B. Evaluation of low-energy extracorporeal
shock-wave application for treatment of chronic plantar fasciitis. J Bone Joint
Surg Am. 2002;84:335-41.
44. Ogden JA, Alvarez R, Levitt R, Cross GL, Marlow M. Shock wave therapy for
chronic proximal plantar fasciitis. Clin Orthop. 2001;387:47-59.
45. Ogden JA, Alvarez RG, Marlow M. Shockwave therapy for chronic proximal
plantar fasciitis: a meta-analysis. Foot Ankle Int. 2002;23:301-8.

22. Wang CJ, Wang FS, Yang KD, Weng LH, Hsu CC, Huang CS, Yang LC. Shock
wave therapy induces neovascularization at the tendon-bone junction. A study
in rabbits. J Orthop Res. 2003;21:984-9.

46. Buch M, Knorr U, Fleming L, Theodore G, Amendola A, Bachmann C, Zingas
C, Siebert WE. [Extracorporeal shockwave therapy in symptomatic heel
spurs. An overview.] Orthopäde. 2002;31:637-44. German.

23. McClure SR, Van Sickle D, White MR. Effects of extracorporeal shock wave
therapy on bone. Vet Surg. 2004;33:40-8.

47. Rompe JD, Decking J, Schoellner C, Nafe B. Shock wave application for
chronic plantar fasciitis in running athletes. A prospective, randomized,
placebo-controlled trial. Am J Sports Med. 2003;31:268-75.

24. Wang FS, Wang CJ, Chen YJ, Chang PR, Huang YT, Sun YC, Huang HC, Yang
YJ, Yang KD. Ras induction of superoxide activates ERK-dependent angio-

48. Abt T, Hopfenmüller W, Mellerowicz H. [Shock wave therapy for recalcitrant


THE JOUR NAL OF BONE & JOINT SURGER Y · JBJS.ORG
VO L U M E 86-A · N U M B E R 10 · O C T O B E R 2004

plantar fasciitis with heel spur: a prospective randomized placebo-controlled
double-blind study.] Z Orthop Ihre Grenzgeb. 2002;140:548-54. German.

E L E C T RO HYD R A U L I C H I G H -E N E R G Y S H O C K -WAVE
TRE A T M E N T F O R C H RO N I C P L A N T A R F A S C I I T I S

58. Yong R, Karas TJ, Smith KD, Petrov O. The durability of the SemmesWeinstein 5.07 monofilament. J Foot Ankle Surg. 2000;39:34-8.

49. Buchbinder R, Ptasznik R, Gordon J, Buchanan J, Prabaharan V, Forbes A.
Ultrasound-guided extracorporeal shock wave therapy for plantar fasciitis: a
randomized controlled trial. JAMA. 2002;288:1364-72.

59. Ware JE Jr, Snow KK, Kosinski M, Gandek KB. SF-36 health survey. Manual
and interpretation guide. Boston: The Health Institute, New England Medical
Center; 1993.

50. Haake M, Buch M, Schoellner C, Goebel F, Vogel M, Mueller I, Hausdorf J,
Zamzow K, Schade-Brittinger C, Mueller HH. Extracorporeal shock wave
therapy for plantar fasciitis: randomised controlled multicentre trial. BMJ.
2003;327:75-9.

60. Ogden JA, Toth-Kischkat A, Schultheiss R. Principles of shock wave therapy.
Clin Orthop. 2001;387:8-17.

51. Speed CA, Nichols D, Wies J, Humphreys H, Richards C, Burnet S, Hazleman BL. Extracorporeal shock wave therapy for plantar fasciitis. A double
blind randomised controlled trial. J Orthop Res. 2003;21:937-40.
52. Alvarez R. Preliminary results on the safety and efficacy of the OssaTron for
treatment of plantar fasciitis. Foot Ankle Int. 2002;23:197-203.
53. Henney JE. From the Food and Drug Administration: shock wave for heel pain.
JAMA. 2000;284:2711.
54. Atkins CJ, Zielinski A, Makosinski A. Palpometry: a novel concept in pain
measurement. Nat Med. 1995;1:1138-9.
55. Bendtsen L, Jensen R, Jensen NK, Olesen J. Muscle palpation with controlled finger pressure: new equipment for the study of tender myofascial
tissues. Pain. 1994;59:235-9.
56. Bell-Krotoski JA, Fess EE, Figarola JH, Hiltz D. Threshold detection and
Semmes-Weinstein monofilaments. J Hand Ther. 1995;8:155-62.
57. McGill M, Molyneaux L, Yue DK. Use of the Semmes-Weinstein 5.07/10 gram
monofilament: the long and the short of it. Diabet Med. 1998;15:615-7.

61. Roles NC, Maudsley RH. Radial tunnel syndrome: resistant tennis elbow as
a nerve entrapment. J Bone Joint Surg Br. 1972;54:499-508.
62. Lee GP, Ogden JA, Cross GL. Effect of extracorporeal shock waves on calcaneal bone spurs. Foot Ankle Int. 2003;24:927-30.
63. Crawford F, Atkins D, Edwards J. Interventions for treating plantar heel pain.
Cochrane Database Syst Rev. 2000;3:CD000416.
64. Martin RL, Irrgang JJ, Conti SF. Outcome study of subjects with insertional
plantar fasciitis. Foot Ankle Int. 1998;19:803-11.
65. Weil LS Jr, Roukis TS, Weil LS, Borrelli AH. Extracorporeal shock wave therapy for the treatment of chronic plantar fasciitis: indications, protocol, intermediate results, and a comparison of results to fasciotomy. J Foot Ankle
Surg. 2002;41:166-72.
66. Fuselier HA, Prats L, Fontenot C, Gauthier A Jr. Comparison of mobile lithotripters at one institution: healthtronics lithotron, Dornier MFL-5000, and
Dornier Doli. J Endourol. 1999;13:539-42.
67. Ogden JA, Cross GL, Williams SS. Bilateral chronic proximal plantar fasciopathy: treatment with electrohydraulic orthotripsy. Foot Ankle Int. 2004;25:
298-302.

